Intravenous administration of antisense oligonucleotides for the treatment of pain

Abstract

Inventors have synthetized 2′-O>-2-methoxyethyl-modified FXYD2-LASO (FXYD2-LASO-Gapmer) and injected them intravenously, a less invasive administration route. The intravenous administration of FXYD2 optimized antisense oligonucleotide (LASO) with MOE allows a long-time effect on the pain compared to an intrathecal administration. Inventors have demonstrated this long-lasting effect on neuropathic pain in the Spinal Nerve Ligation (SNL) rat model and inflammatory pain in the Complete Freund's Adjuvant (CFA)-induced rat model. Accordingly, the invention relates to antisense oligonucleotide targeting FXYD2 for use in the treatment of pain, wherein said antisense oligonucleotide is administered intravenously.

Dependencies are inferred from the claim text.